Early efficacy data for AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s antibody-drug conjugate (ADC) datopotamab deruxtecan in triple-negative breast cancer may bolster the drug’s position as a worthy successor to the two companies’ previously approved ADC, as well as a potential competitor against an approved Gilead Sciences, Inc. drug with the same target that has produced similar response rates.
The partners unveiled new data on 8 May from the triple-negative breast cancer (TNBC) cohort of the Phase I TROPION-PanTumor01...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?